Discover the Potential of Assura plc with Strategic Buy

Assura plc is a UK-based healthcare property investment company that has been making strategic moves to enhance its portfolio. With a strong focus on primary care, Assura has a significant presence in the UK market.

Its portfolio consists of over 600 properties, including medical centers, surgeries, and other healthcare facilities. This extensive network provides a solid foundation for future growth and expansion.

Assura's strategic buy of a portfolio of 35 properties from a rival company in 2020 marked a significant milestone in its expansion strategy. This acquisition has helped the company to increase its presence in key regions and strengthen its position in the market.

By investing in primary care, Assura is well-positioned to benefit from the growing demand for healthcare services in the UK.

Explore further: Private Equity Market Trends

Assura plc's current stock price has opened at 42.00 and reached a high of 42.06, with a low of 41.64.

The company's market capitalization is 1.36 billion GBP.

Assura plc has an average volume of 15.76 million shares.

The company's shares outstanding total 3.25 billion, with 2.98 billion shares in free float.

Its Price-to-Earnings (P/E) ratio is 19.44.

The company's Earnings Per Share (EPS) is 0.0215 GBP.

Assura plc pays an annual dividend of 3.36 GBX, with an annual dividend yield of 8.05%.

Here are the key dividend dates:

Assura PLC has a unique business model that sets it apart from other real estate investment trusts. They specialize in developing and managing primary care properties across the UK.

Their focus on primary care properties allows them to create and maintain robust and modern facilities that serve as the backbone for general practitioners, dentists, and other community health services.

Assura's partnership with the National Health Service (NHS) ensures that these facilities meet current standards and anticipate future healthcare needs, ensuring long-term sustainability and growth opportunities.

Revenue generation for Assura PLC primarily revolves around rental income derived from leasing healthcare properties.

With a portfolio spanning several hundred properties, Assura capitalizes on long-term leases, often with inflation-linked rent reviews, providing them with a stable and predictable income.

This strategy minimizes vacancy risks, given their collaboration with the NHS and the ongoing demand for modern healthcare facilities.

Assura's focus on niche real estate like medical centers and community hospitals aligns its financial objectives with the critical needs of public health infrastructure.

Assura plc is a strategic buy with promising growth prospects. Analyst John Cahill from Stifel Nicolaus maintained a Buy rating on the stock with a price target of £55.00.

The attractive dividend yield of 8.7% is one of the key reasons for this recommendation. This yield is significantly higher than that of its peer, Primary Health Properties, which offers a 7.3% yield.

Assura is trading at a notable discount to its Net Tangible Assets (NTA), at -22%. This is below both the broader Real Estate Investment Trust (REIT) sector and Primary Health Properties.

A 10% earnings growth over the next three years is expected, underscoring the potential for value appreciation. This makes a Buy rating a strategic recommendation.

Corporate insider activity is also positive, with 72 insiders buying their shares of AGR over the past quarter. This increase in insider buying is a good sign for investors.

Here are some key statistics to consider:

Berenberg Bank also maintains a Buy rating on the stock with a price target of £48.00.